Pharmaceuticals - Top 5 Emerging Industries Market Overview (Market size, Segmentation and Trends Analysis)

Pharmaceuticals - Top 5 Emerging Markets Industry Guide Add to your bookmarks!

$ 995 - November 2012 - by MarketLine - 138

Summary

Table of Contents

View Report

Search Inside

Data Series

Industry

Pharmaceutical

Country

Mexico
India
Brazil
China
South Africa

Companies

Jiangsu Yangtze River Pharmaceutical Group Company Ltd.
Lilly and Co.
Eli Lilly and Co.
AstraZeneca PLC
Lupin Ltd.
Ranbaxy Laboratories Ltd.
Cipla Ltd.
GlaxoSmithKline P.L.C.
GlaxoSmithKline PLC
Pfizer Inc.
Dr Reddy's Laboratories Ltd.

Pharmaceuticals - Top 5 Emerging Markets Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry in each of the Top 5 Emerging markets (Brazil, China, India, Mexico and South Africa). The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market.

Scope of the Report

* Contains an executive summary and data on value, volume and segmentation

* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies

* Incorporates in-depth five forces competitive environment analysis and scorecards

* Compares data from Brazil, China, India, Mexico and South Africa, alongside individual chapters on each country. .

* Includes a five-year forecast of the industry

Highlights

The top 5 emerging countries contributed $101.8 billion to the global pharmaceuticals industry in 2011, with a compound annual growth rate (CAGR) of 15.5% between 2007 and 2011. The top 5 emerging countries are expected to reach a value of $185.3 billion in 2016, with a CAGR of 12.7% over the 2011-16 period.

Within the pharmaceuticals industry, China is the leading country among the top 5 emerging nations, with market revenues of $55.4 billion in 2011.

China is expected to lead the pharmaceuticals industry in the top five emerging nations, with a value of $108.1 billion in 2016, followed by Brazil and India with expected values of $29.0 and $27.3 billion, respectively.

Why you should buy this report

* Spot future trends and developments

* Inform your business decisions

* Add weight to presentations and marketing materials

* Save time carrying out entry-level research

Market Definition

The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.
Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors).
Any currency conversions used in the production of this report have been calculated at constant 2011 annual average exchange rates.

TABLE OF CONTENTS
Introduction 11
What is this report about? 11
Who is the target reader? 11
How to use this report 11
Definitions 11
Top 5 Emerging Countires Pharmaceuticals Industry Outlook 12
Pharmaceuticals in South Africa 15
Market Overview 15
Market Data 16
Market Segmentation 17
Market outlook 19
Five forces analysis 20
Leading companies 28
Macroeconomic indicators 38
Pharmaceuticals in Brazil 40
Market Overview 40
Market Data 41
Market Segmentation 42
Market outlook 44
Five forces analysis 45
Leading companies 53
Macroeconomic indicators 59
Pharmaceuticals in China 61
Market Overview 61
Market Data 62
Market Segmentation 63
Market outlook 65
Five forces analysis 66
Leading companies 74
Macroeconomic indicators 82
Pharmaceuticals in India 84
Market Overview 84
Market Data 85
Market Segmentation 86
Market outlook 88
Five forces analysis 89
Leading companies 97
Macroeconomic indicators 110
Pharmaceuticals in Mexico 112
Market Overview 112
Market Data 113
Market Segmentation 114
Market outlook 116
Five forces analysis 117
Leading companies 125
Macroeconomic indicators 135
Appendix 137
Methodology 137

LIST OF TABLES
Table 1: Top 5 emerging countries pharmaceuticals industry, revenue ($bn), 2007-16 12
Table 2: Top 5 emerging countries pharmaceuticals industry, revenue ($bn), 2007-11 13
Table 3: Top 5 emerging countries pharmaceuticals industry forecast, revenue ($bn), 2011-16 14
Table 4: South Africa pharmaceuticals market value: $ billion, 2007–11 16
Table 5: South Africa pharmaceuticals market geography segmentation: $ million, 2007–2011 17
Table 6: South Africa pharmaceuticals market share: % share, by value, 2011 18
Table 7: South Africa pharmaceuticals market value forecast: $ billion, 2011–16 19
Table 8: Pfizer Inc.: key facts 28
Table 9: Pfizer Inc.: key financials ($) 29
Table 10: Pfizer Inc.: key financial ratios 29
Table 11: GlaxoSmithKline Plc: key facts 31
Table 12: GlaxoSmithKline Plc: key financials ($) 32
Table 13: GlaxoSmithKline Plc: key financials (£) 33
Table 14: GlaxoSmithKline Plc: key financial ratios 33
Table 15: Aspen Pharmacare Holdings Ltd: key facts 35
Table 16: Aspen Pharmacare Holdings Ltd: key financials ($) 36
Table 17: Aspen Pharmacare Holdings Ltd: key financials (ZAR) 36
Table 18: Aspen Pharmacare Holdings Ltd: key financial ratios 36
Table 19: South Africa size of population (million), 2007–11 38
Table 20: South Africa gdp (constant 2000 prices, $ billion), 2007–11 38
Table 21: South Africa gdp (current prices, $ billion), 2007–11 38
Table 22: South Africa inflation, 2007–11 39
Table 23: South Africa consumer price index (absolute), 2007–11 39
Table 24: South Africa exchange rate, 2007–11 39
Table 25: Brazil pharmaceuticals market value: $ billion, 2007–11 41
Table 26: Brazil pharmaceuticals market geography segmentation: $ billion, 2011 42
Table 27: Brazil pharmaceuticals market share: % share, by value, 2011 43
Table 28: Brazil pharmaceuticals market value forecast: $ billion, 2011–16 44
Table 29: Aché Laboratórios Farmacêuticos S.A.: key facts 53
Table 30: Medley Indústria Farmacêutica Ltd: key facts 54
Table 31: Sanofi: key facts 55
Table 32: Sanofi: key financials ($) 56
Table 33: Sanofi: key financials (€) 56
Table 34: Sanofi: key financial ratios 56
Table 35: EMS Sigma Pharma: key facts 58
Table 36: Brazil size of population (million), 2007–11 59
Table 37: Brazil gdp (constant 2000 prices, $ billion), 2007–11 59
Table 38: Brazil gdp (current prices, $ billion), 2007–11 59
Table 39: Brazil inflation, 2007–11 60
Table 40: Brazil consumer price index (absolute), 2007–11 60
Table 41: Brazil exchange rate, 2007–11 60
Table 42: China pharmaceuticals market value: $ billion, 2007–11 62
Table 43: China pharmaceuticals market geography segmentation: $ billion, 2011 63
Table 44: China pharmaceuticals market share: % share, by value, 2011 64
Table 45: China pharmaceuticals market value forecast: $ billion, 2011–16 65
Table 46: Pfizer Inc.: key facts 74
Table 47: Pfizer Inc.: key financials ($) 75
Table 48: Pfizer Inc.: key financial ratios 75
Table 49: AstraZeneca PLC: key facts 77
Table 50: AstraZeneca PLC: key financials ($) 78
Table 51: AstraZeneca PLC: key financial ratios 79
Table 52: Jiangsu Yangtze River Pharmaceutical Group Company Ltd.: key facts 81
Table 53: China size of population (million), 2007–11 82
Table 54: China gdp (constant 2000 prices, $ billion), 2007–11 82
Table 55: China gdp (current prices, $ billion), 2007–11 82
Table 56: China inflation, 2007–11 83
Table 57: China consumer price index (absolute), 2007–11 83
Table 58: China exchange rate, 2007–11 83
Table 59: India pharmaceuticals market value: $ billion, 2007–11 85
Table 60: India pharmaceuticals market geography segmentation: $ billion, 2011 86
Table 61: India pharmaceuticals market share: % share, by value, 2011 87
Table 62: India pharmaceuticals market value forecast: $ billion, 2011–16 88
Table 63: Dr. Reddy's Laboratories Limited: key facts 97
Table 64: Dr. Reddy's Laboratories Limited: key financials ($) 98
Table 65: Dr. Reddy's Laboratories Limited: key financials (Rs.) 98
Table 66: Dr. Reddy's Laboratories Limited: key financial ratios 98
Table 67: Cipla Limited: key facts 100
Table 68: Cipla Limited: key financials ($) 101
Table 69: Cipla Limited: key financials (Rs.) 101
Table 70: Cipla Limited: key financial ratios 101
Table 71: Ranbaxy Laboratories Limited: key facts 103
Table 72: Ranbaxy Laboratories Limited: key financials ($) 104
Table 73: Ranbaxy Laboratories Limited: key financials (Rs.) 104
Table 74: Ranbaxy Laboratories Limited: key financial ratios 104
Table 75: Lupin Limited: key facts 106
Table 76: Lupin Limited: key financials ($) 107
Table 77: Lupin Limited: key financials (Rs.) 107
Table 78: Lupin Limited: key financial ratios 108
Table 79: India size of population (million), 2007–11 110
Table 80: India gdp (constant 2000 prices, $ billion), 2007–11 110
Table 81: India gdp (current prices, $ billion), 2007–11 110
Table 82: India inflation, 2007–11 111
Table 83: India consumer price index (absolute), 2007–11 111
Table 84: India exchange rate, 2007–11 111
Table 85: Mexico pharmaceuticals market value: $ billion, 2007–11 113
Table 86: Mexico pharmaceuticals market geography segmentation: $ billion, 2011 114
Table 87: Mexico pharmaceuticals market share: % share, by value, 2011 115
Table 88: Mexico pharmaceuticals market value forecast: $ billion, 2011–16 116
Table 89: Eli Lilly and Company: key facts 125
Table 90: Eli Lilly and Company: key financials ($) 126
Table 91: Eli Lilly and Company: key financial ratios 126
Table 92: Pfizer Inc.: key facts 128
Table 93: Pfizer Inc.: key financials ($) 129
Table 94: Pfizer Inc.: key financial ratios 129
Table 95: GlaxoSmithKline Plc: key facts 131
Table 96: GlaxoSmithKline Plc: key financials ($) 132
Table 97: GlaxoSmithKline Plc: key financials (£) 133
Table 98: GlaxoSmithKline Plc: key financial ratios 133
Table 99: Mexico size of population (million), 2007–11 135
Table 100: Mexico gdp (constant 2000 prices, $ billion), 2007–11 135
Table 101: Mexico gdp (current prices, $ billion), 2007–11 135
Table 102: Mexico inflation, 2007–11 136
Table 103: Mexico consumer price index (absolute), 2007–11 136
Table 104: Mexico exchange rate, 2007–11 136

LIST OF FIGURES
Figure 1: South Africa pharmaceuticals market value: $ billion, 2007–11 16
Figure 2: South Africa pharmaceuticals market geography segmentation: % share, by value, 2007,2011 17
Figure 3: South Africa pharmaceuticals market share: % share, by value, 2011 18
Figure 4: South Africa pharmaceuticals market value forecast: $ billion, 2011–16 19
Figure 5: Forces driving competition in the pharmaceuticals market in South Africa, 2011 20
Figure 6: Drivers of buyer power in the pharmaceuticals market in South Africa, 2011 21
Figure 7: Drivers of supplier power in the pharmaceuticals market in South Africa, 2011 23
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in South Africa, 2011 24
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in South Africa, 2011 26
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in South Africa, 2011 27
Figure 11: Pfizer Inc.: revenues & profitability 30
Figure 12: Pfizer Inc.: assets & liabilities 30
Figure 13: GlaxoSmithKline Plc: revenues & profitability 33
Figure 14: GlaxoSmithKline Plc: assets & liabilities 34
Figure 15: Aspen Pharmacare Holdings Ltd: revenues & profitability 37
Figure 16: Aspen Pharmacare Holdings Ltd: assets & liabilities 37
Figure 17: Brazil pharmaceuticals market value: $ billion, 2007–11 41
Figure 18: Brazil pharmaceuticals market geography segmentation: % share, by value, 2011 42
Figure 19: Brazil pharmaceuticals market share: % share, by value, 2011 43
Figure 20: Brazil pharmaceuticals market value forecast: $ billion, 2011–16 44
Figure 21: Forces driving competition in the pharmaceuticals market in Brazil, 2011 45
Figure 22: Drivers of buyer power in the pharmaceuticals market in Brazil, 2011 46
Figure 23: Drivers of supplier power in the pharmaceuticals market in Brazil, 2011 48
Figure 24: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Brazil, 2011 49
Figure 25: Factors influencing the threat of substitutes in the pharmaceuticals market in Brazil, 2011 51
Figure 26: Drivers of degree of rivalry in the pharmaceuticals market in Brazil, 2011 52
Figure 27: Sanofi: revenues & profitability 57
Figure 28: Sanofi: assets & liabilities 57
Figure 29: China pharmaceuticals market value: $ billion, 2007–11 62
Figure 30: China pharmaceuticals market geography segmentation: % share, by value, 2011 63
Figure 31: China pharmaceuticals market share: % share, by value, 2011 64
Figure 32: China pharmaceuticals market value forecast: $ billion, 2011–16 65
Figure 33: Forces driving competition in the pharmaceuticals market in China, 2011 66
Figure 34: Drivers of buyer power in the pharmaceuticals market in China, 2011 67
Figure 35: Drivers of supplier power in the pharmaceuticals market in China, 2011 69
Figure 36: Factors influencing the likelihood of new entrants in the pharmaceuticals market in China, 2011 70
Figure 37: Factors influencing the threat of substitutes in the pharmaceuticals market in China, 2011 72
Figure 38: Drivers of degree of rivalry in the pharmaceuticals market in China, 2011 73
Figure 39: Pfizer Inc.: revenues & profitability 76
Figure 40: Pfizer Inc.: assets & liabilities 76
Figure 41: AstraZeneca PLC: revenues & profitability 79
Figure 42: AstraZeneca PLC: assets & liabilities 80
Figure 43: India pharmaceuticals market value: $ billion, 2007–11 85
Figure 44: India pharmaceuticals market geography segmentation: % share, by value, 2011 86
Figure 45: India pharmaceuticals market share: % share, by value, 2011 87
Figure 46: India pharmaceuticals market value forecast: $ billion, 2011–16 88
Figure 47: Forces driving competition in the pharmaceuticals market in India, 2011 89
Figure 48: Drivers of buyer power in the pharmaceuticals market in India, 2011 90
Figure 49: Drivers of supplier power in the pharmaceuticals market in India, 2011 92
Figure 50: Factors influencing the likelihood of new entrants in the pharmaceuticals market in India, 2011 93
Figure 51: Factors influencing the threat of substitutes in the pharmaceuticals market in India, 2011 95
Figure 52: Drivers of degree of rivalry in the pharmaceuticals market in India, 2011 96
Figure 53: Dr. Reddy's Laboratories Limited: revenues & profitability 99
Figure 54: Dr. Reddy's Laboratories Limited: assets & liabilities 99
Figure 55: Cipla Limited: revenues & profitability 102
Figure 56: Cipla Limited: assets & liabilities 102
Figure 57: Ranbaxy Laboratories Limited: revenues & profitability 105
Figure 58: Ranbaxy Laboratories Limited: assets & liabilities 105
Figure 59: Lupin Limited: revenues & profitability 108
Figure 60: Lupin Limited: assets & liabilities 109
Figure 61: Mexico pharmaceuticals market value: $ billion, 2007–11 113
Figure 62: Mexico pharmaceuticals market geography segmentation: % share, by value, 2011 114
Figure 63: Mexico pharmaceuticals market share: % share, by value, 2011 115
Figure 64: Mexico pharmaceuticals market value forecast: $ billion, 2011–16 116
Figure 65: Forces driving competition in the pharmaceuticals market in Mexico, 2011 117
Figure 66: Drivers of buyer power in the pharmaceuticals market in Mexico, 2011 118
Figure 67: Drivers of supplier power in the pharmaceuticals market in Mexico, 2011 120
Figure 68: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Mexico, 2011 121
Figure 69: Factors influencing the threat of substitutes in the pharmaceuticals market in Mexico, 2011 123
Figure 70: Drivers of degree of rivalry in the pharmaceuticals market in Mexico, 2011 124
Figure 71: Eli Lilly and Company: revenues & profitability 127
Figure 72: Eli Lilly and Company: assets & liabilities 127
Figure 73: Pfizer Inc.: revenues & profitability 130
Figure 74: Pfizer Inc.: assets & liabilities 130
Figure 75: GlaxoSmithKline Plc: revenues & profitability 133
Figure 76: GlaxoSmithKline Plc: assets & liabilities 134

Pharmaceutical in Mexico